论文部分内容阅读
近年来在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗领域里程碑式的改变是采用EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变阳性的晚期患者。但大部分患者在使用该药治疗9~11个月后陆续出现耐药现象。研究发现EGFR基因20号外显子T790M基因突变是导致EGFR TKI耐药的最主要因素,因此特异性靶向T790M抗药性突变的EGFR抑制剂AZD9291受到了极大的关注。本文对AZD9291治疗非小细胞肺癌的临床转化进行了综述。
In recent years, a landmark change in the treatment of non-small cell lung cancer (NSCLC) has been the use of the EGFR-tyrosine kinase inhibitor (TKI) to treat epidermal growth factor receptor, EGFR) gene mutation in patients with advanced stage. However, the majority of patients in the use of the drug after 9 to 11 months after another drug resistance. It has been found that the mutation of T790M gene in exon 20 of EGFR gene is the most important factor leading to TKI resistance in EGFR gene. Therefore, EGFR inhibitor AZD9291 that specifically targets T790M resistance mutation has received great attention. This article reviews the clinical transformation of AZD9291 in the treatment of non-small cell lung cancer.